(Q54343194)

28 May 2018

title

Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. (English)

1 reference

28 May 2018

1 reference

Harald Hegen

1

1 reference

28 May 2018

Manuel Schleiser

2

1 reference

28 May 2018

Claudia Gneiss

3

1 reference

28 May 2018

Franziska Di Pauli

4

1 reference

28 May 2018

Rainer Ehling

5

1 reference

28 May 2018

Bettina Kuenz

6

1 reference

28 May 2018

Andreas Lutterotti

7

1 reference

28 May 2018

Thomas Berger

8

1 reference

28 May 2018

Florian Deisenhammer

9

1 reference

28 May 2018

publication date

19 October 2011

1 reference

28 May 2018

Multiple Sclerosis Journal

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

28 May 2018

volume

18

1 reference

28 May 2018

issue

5

1 reference

28 May 2018

page(s)

610-615

1 reference

28 May 2018

Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458511426738

Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511426738

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511426738

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511426738

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511426738

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511426738

Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511426738

High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511426738

Epitope specificity of neutralizing antibodies against IFN-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511426738

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511426738

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511426738

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511426738

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511426738

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511426738

The clinical impact of interferon beta antibodies in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511426738

Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511426738

Interferon-β antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511426738

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511426738

21 January 2018

Identifiers

DOI

10.1177/1352458511426738

1 reference

28 May 2018

PubMed ID

22013146

1 reference

28 May 2018